Zeria Q1 Operating Profit Climbs 28% on Asacol and Veltassa, but Swiss Franc Losses Cut Net Profit 21%

Zeria Pharmaceutical Co., Ltd. (TSE: 4559), the Tokyo-based maker of the ulcerative-colitis therapy Asacol and of the Hepalyse, Chondroitin and With-One over-the-counter brands, reported consolidated first-quarter results for the year ending March 2027 under Japanese GAAP. Net sales for the three months to June 30 rose 10.1% to ¥21,448 million and operating profit jumped 28.3% to ¥1,950 million. Below that line, however, the picture inverted: ordinary profit fell 13.8% to ¥1,432 million and profit attributable to owners of the parent dropped 20.6% to ¥866 million. Basic earnings per share came to ¥19.65, against ¥24.75 a year earlier.

Currency losses open a gap between the operating and ordinary lines

The distance between those two profit lines is the story of the quarter. Operating profit of ¥1,950 million sat ¥518 million above ordinary profit of ¥1,432 million, meaning non-operating and financial items subtracted more than half a billion yen. A year earlier the relationship ran the other way: ordinary profit of ¥1,662 million exceeded operating profit of ¥1,520 million by ¥142 million. The year-on-year swing in the items sitting between the two lines therefore comes to roughly ¥660 million, and the company attributes it to foreign-exchange losses. Zeria runs a European business built around Asacol, and during the April-to-June quarter the Swiss franc strengthened against the euro, sterling and other European currencies, generating currency losses on the group's franc-linked positions. Because those losses land below operating profit, the operating result was untouched while ordinary profit and the bottom line both fell. One measure moved decisively the other way: comprehensive income was a positive ¥769 million, against a negative ¥1,116 million a year earlier, as translation adjustments on overseas net assets swung in the group's favour even as transactional currency losses hit the income statement.

Prescription pharmaceuticals carry the top line

Prescription Pharmaceuticals, the larger of Zeria's two operating businesses, lifted net sales 13.5% to ¥14,379 million — roughly two-thirds of group revenue and the source of essentially all the quarter's growth. Overseas, Asacol, the mesalazine formulation for ulcerative colitis that anchors the company's international presence, continued to perform solidly. In Japan, Veltassa, the hyperkalaemia treatment launched in March last year, gained market penetration as the company stepped up promotional activity behind it; a product in its second year on the market is now contributing visibly to domestic growth. Segment profit rose to ¥2,195 million from ¥1,716 million, an increase of 27.9%, so profitability improved faster than revenue — a sign that the incremental sales came at healthy margins rather than being bought through discounting.

Consumer healthcare grows more slowly as OTC competition bites

The Consumer Healthcare business raised net sales 3.6% to ¥7,032 million, a far more modest advance and one achieved against a slowing Japanese over-the-counter market. Within the main product lines the Hepalyse family grew, led by Hepalyse W sold through convenience stores and supported by aggressive advertising and sales promotion. Working the other way, the Chondroitin and With-One families declined under competitive pressure as growth in the overall OTC market cooled. Segment profit edged up 1.9% to ¥1,362 million from ¥1,336 million — the promotional spending behind Hepalyse largely consumed the benefit of the extra revenue. The residual Other segment, covering insurance agency work and real-estate rental income, contributed ¥37 million of sales, down 3.6%, and ¥54 million of profit. Reportable segment profit totalled ¥3,558 million against ¥3,053 million a year earlier; adjustments of −¥1,661 million (mainly unallocated general and administrative expenses, versus −¥1,587 million) bridge the total of ¥3,612 million down to the consolidated operating profit of ¥1,950 million.

A receivables unwind trims the balance sheet

Total assets fell ¥5,012 million over the three months to ¥174,685 million from ¥179,697 million at the March year-end. Current assets declined ¥2,871 million to ¥79,775 million, driven by a ¥5,072 million reduction in accounts receivable — the normal unwind of the fiscal-year-end collection cycle — partly offset by a ¥1,631 million build in merchandise and finished-goods inventories. Non-current assets fell ¥2,141 million to ¥94,909 million, including a ¥1,159 million decline in intangible fixed assets. Total liabilities dropped ¥4,680 million to ¥66,413 million, almost entirely through a ¥4,216 million reduction in current liabilities. Net assets were broadly flat at ¥108,272 million against ¥108,604 million, with shareholders' equity of ¥108,039 million. Because the asset base shrank while equity held, the equity ratio improved to 61.8% from 60.3% — a balance sheet that is, if anything, a little sturdier than it was at the year-end.

Guidance held, and it implies a much stronger rest of the year

Zeria left its forecast for the year to March 2027 unchanged from the previous announcement: net sales of ¥95,000 million (+6.6%), operating profit of ¥13,000 million (+5.1%), ordinary profit of ¥13,000 million (+17.7%) and profit attributable to owners of the parent of ¥10,000 million (+18.3%), for forecast earnings per share of ¥226.86. The first-half targets are net sales of ¥45,000 million (+12.6%), operating profit of ¥6,000 million (+64.8%), ordinary profit of ¥6,000 million (+125.9%) and net profit of ¥4,000 million (+130.2%), with EPS of ¥90.75. Those figures set a demanding bar. First-quarter operating profit of ¥1,950 million is only 32.5% of the ¥6,000 million half-year target and 15.0% of the ¥13,000 million full-year target, so the plan implies a materially stronger second quarter and second half — and, on the ordinary-profit line, a currency environment that stops working against the company. The dividend forecast was likewise unchanged: an interim of ¥25.00 and a year-end of ¥25.00 for an annual ¥50.00, up from ¥49.00 for the year just ended, which comprised ¥24.00 at the interim and ¥25.00 at the year-end. Management under president and chief operating officer Mitsuhiro Ibe revised no part of the previously announced plan.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.